Historique
Rapport
New heroin-assisted treatment. Recent evidence and current practices of supervised injectable heroin treatment in Europe and beyond
(Nouveau traitement avec prescription d'héroïne)
Auteur(s) :
STRANG, J. ;
GROSHKOVA, T. ;
METREBIAN, N.
Année
2012
Page(s) :
170 p.
Sous-type de document :
Revue de la littérature / Literature review
Langue(s) :
Anglais
Collection :
Insights, n°11
ISBN :
978-92-9168-495-3
Domaine :
Drogues illicites / Illicit drugs
Thésaurus mots-clés
TRAITEMENT
;
HEROINE
;
INJECTION
;
DISTRIBUTION CONTROLEE
;
EVALUATION
;
COUT
;
TRAITEMENT DE MAINTENANCE
;
DONNEE PROBANTE
Thésaurus géographique
EUROPE
;
INTERNATIONAL
;
SUISSE
;
PAYS-BAS
;
ESPAGNE
;
ALLEMAGNE
;
CANADA
;
ROYAUME-UNI
Note générale :
Communiqué du 19/04/2012 : "Premier état des lieux sur le nouveau traitement avec prescription d'héroïne. Nouveau rapport de l'OEDT présente les derniers éléments disponibles sur le traitement à l'héroïne destiné aux usagers d'opiacés difficiles à traiter"
http://www.emcdda.europa.eu/news/2012/1
http://www.emcdda.europa.eu/news/2012/1
Note de contenu :
TABLE OF CONTENTS:
• Chapter 1: Introduction to this EMCDDA Insights
• Chapter 2: Development of supervised injectable heroin treatment in Europe and beyond
• Chapter 3: Scientific evidence base for supervised injectable heroin treatment
• Chapter 4: Economic evaluation of supervised injectable heroin treatment
• Chapter 5: Pharmaceutical diacetylmorphine products
• Chapter 6: Implementation and clinical practice of supervised injectable heroin treatment in Europe and beyond
• Chapter 7: Conclusions
• Chapter 1: Introduction to this EMCDDA Insights
• Chapter 2: Development of supervised injectable heroin treatment in Europe and beyond
• Chapter 3: Scientific evidence base for supervised injectable heroin treatment
• Chapter 4: Economic evaluation of supervised injectable heroin treatment
• Chapter 5: Pharmaceutical diacetylmorphine products
• Chapter 6: Implementation and clinical practice of supervised injectable heroin treatment in Europe and beyond
• Chapter 7: Conclusions
Résumé :
The prescription of substitution drugs, such as methadone and buprenorphine, has become a mainstream, first-line treatment for opioid dependence, with around 700 000 of Europe's 1.3 million problem opioid users receiving substitution treatment today. But a small minority of entrenched opioid users repeatedly fails to respond to interventions of this kind. Findings from international trials now suggest that the supervised use of medicinal heroin can be an effective second-line treatment for this small, and previously unresponsive, group. In this latest EMCDDA Insights report, experts describe the development as 'an important clinical step forward'. The report provides the first state-of-the-art overview of research on the subject, examining the latest evidence and clinical experience in this area in Europe and beyond.
Affiliation :
National Addiction Centre, Institute of Psychiatry, King's College London, UK